The United Kingdom is earmarking more than £100 million of its overseas aid budget to support pioneering research into vaccines, medicines and diagnostics for diseases such as malaria, dengue, HIV, tuberculosis and pre‑eclampsia, despite broader cuts to the aid programme.
Funding Commitment and Partnerships
The government will allocate £137.5 million over the financial years 2024/25 to 2027/28 to ten product‑development partnerships. These include collaborations with King’s College London, the Drugs for Neglected Diseases initiative and the TB Alliance. Development minister Kirsty McNeill told The Independent, “We’re continuing the UK’s proud track record of supporting science that saves lives.” She added that British work on new malaria vaccines and bed nets had “contributed to one million lives saved from malaria in 2024 alone”.
Maternal and Neonatal Health Focus
At King’s College London, researchers are developing affordable diagnostic tools and a mobile application designed to alert frontline health workers to maternal health risks, notably pre‑eclampsia and anaemia. This effort responds to growing concern among charities that aid reductions could jeopardise progress in maternal and neonatal outcomes.
Tuberculosis and Malaria Innovations
The TB Alliance partnership backs scientists working on safer, shorter and more affordable tuberculosis regimens; earlier UK support helped deliver Pretomanid, a drug used to treat drug‑resistant TB. Meanwhile, alliances with the Medicines for Malaria Venture (MMV) and the World Mosquito Programme aim to keep the UK at the forefront of malaria research. MMV‑backed scientists at the University of Dundee recently unveiled a single‑dose malaria drug that could transform treatment worldwide. Dr Martin Fitchet, CEO of MMV, said, “The UK’s partnership with MMV has helped transform cutting‑edge research into practical solutions for people at risk of malaria, contributing to medicines that are already saving lives and supporting the development of the next generation of antimalarials.”
Context of Wider Aid Cuts
The funding announcement arrives as the UK implements wide‑ranging cuts to its aid budget, following former prime minister Keir Starmer’s decision to reduce spending by nearly 40 percent. Nine African countries have experienced a decline of more than 80 percent in UK bilateral aid as a result. The move comes just weeks after Ed Miliband assumed the role of foreign secretary, pledging to prioritise international development and the climate crisis. The article forms part of The Independent’s Rethinking Global Aid project.
Why it Matters
Sustaining investment in global health research protects hard‑won gains against diseases that still claim millions of lives each year, while also reinforcing the UK’s scientific leadership at a time when its aid budget is being curtailed. By channelling funds into partnerships that produce affordable diagnostics, shorter treatment courses and next‑generation vaccines, the government aims to offset the adverse effects of aid reductions and ensure that breakthroughs continue to reach the most vulnerable populations worldwide.
